The funding round was led by Cambridge Enterprise with backing from Cambridge Angels, SyndicateRoom and Camvision.
"The team has done a fantastic job so far and Mario will continue to work closely with Michael as we ramp up production and bring new products to market,"
Cambridge Enterprise backed the primary fixed income technology provider in its latest funding round.
"Our mission is to help optimise financial services by leveraging collective scale and intelligence for the benefit of all. We do this by making asset sourcing and placement faster, cheaper, and better."
The oversubscribed round was led by Cambridge Enterprise and will fund the company's transition into drug development.
"We are pleased to welcome on board our new investors and appreciate their confidence in our business. Our aim is to replicate the specificity of biologics in the powerful and scalable form of a small molecule, to treat devastating diseases where there are currently no treatment options. We have proven the strength of our platform in tapping unexplored parts of the chemical universe to find novel and specific hits for currently undruggable targets, and are excited to now be able to invest in our own pipeline of drug discovery programmes, as well as to develop further strategic partnerships."
Parkwalk led the series A round with participation from life science investors and angels to fund international expansion and senior hires.
"There is a clear market need for high-quality protein reagents, especially for applications in stem cell biology and organoid research. Qkine has both a compelling technology to meet this need and a highly experienced management team to drive the growth of the business."
The investment round was led by Parkwalk Advisors and Foresight Williams Technology EIS Fund.
"The energy efficiency of many products could be greatly improved if they incorporated gas and flow sensors, but companies are unable to do so due to cost, size, or manufacturing constraints. Our vision is to bring flow- and gas-sensing technologies to all these products. This funding round helps us to scale up and bring our vision to reality."
